Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 1,641

Document Document Title
JP6152104B2
The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method o...  
JP2017095358A
To provide a compound having nitrogen monooxide production promoting effect, blood vessel protecting effect, trace quantity albumin urine suppressing effect or the like superior to tetrahydrobiopterin (BH4), for compensating reduction of...  
JP2017513820A
The present invention relates to an active substance of an inorganic cation and organic negative ion, and an inorganic organicity hybrid compound as an ionic compound which comprises organic negative ion fluorescence pigment arbitrarily....  
JP2017512831A
Formula (I) : of (2, 4* dihydroxy *5* isopropyl * phenyl) * [5* (4* methyl * Piperazine *1* ylmethyl) *1 and 3* dihydro* isoindole *2* Il ] * meta-non, Or the prescription thing in the phosphoric acid buffer or succinic acid buffer of th...  
JP6134441B2
It has been surprisingly been found that the compounds of general formula I are positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4), useful for the treatment of Parkinson's disease, anxiety, emesis, obsess...  
JP2017512186A
The present invention provides the compound denoted by formula (I), and its medicine constituent. It is thought that the compound denoted by formula (I) is a binder of a Bromo domain and/or Bromo domain content protein (for example, Brom...  
JP2017511357A
[Subject] Those use as the new molecular entity which modulates the activity of RORgamma, and a medicine is provided. [Means for Solution] The present invention is RORgamma. Abnormal conditions and RORgamma Formula (I) suitable for medic...  
JP6114820B2
Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the f...  
JPWO2015125892A1
The present invention is general formula (I). [-izing 1](The inside of a formula and Z are [-izing 2].) Indicate . Y1 Is N and CR1An example, Y2 Is N and CR2An example, Y3 Is N and CR3An example, Y4 Is N and CR4R in an example and these ...  
JP6104377B2
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.  
JP6093759B2
The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating...  
JP6084967B2
To provide a method for producing sepiapterin, lactoylpterin or tetrahydrolactoylpterin. Sepiapterin, lactoylpterin and tetrahydrolactoylpterin are produced at high yield through the following reaction scheme.  
JP6072308B2
The present invention relates to spiroheterocycl-dihydropyhmidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which int...  
JP6057947B2
This invention is in the field of chemical restructuring of antimetabolite agents known to have poor oral bioavailability and to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concer...  
JP2016216464A
To provide molecules which can control the activity of an osteoprotegerin ligand (OPGL) in the therapy of osteopenia.The invention relates to an antibody that interacts with OPGL and inhibits osteoclastic differentiation and the binding ...  
JP6027610B2
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, incl...  
JP2016528242A
The present invention is turned to 5 and hemi sulfate of 10* methylene * (6R) * tetrahydrofolic acid which are on a crystalline material form substantially preferably, a medicine constituent and its medical treatment, preferably the use ...  
JP2016525532A
the present invention -- the mullet for the disposal of myelodysplastic syndromes (MDS) -- it is related with use of Serify , its salt permitted pharmacologically, or its hydrate.  
JP5972867B2  
JP2015516405A5  
JP5942133B2  
JP5937087B2
The present invention relates to an improved process for manufacturing dihydropteridinones of general formula (12) as well as intermediates thereof, wherein the groups R1, R2, R3, R4, and R5 have the meanings given in the claims and spec...  
JP2016516766A
The glutar imide derivative or its salt permitted pharmacologically of general formula (I) with biological activity with the new present invention, It is related with the method for manufacturing the glutar imide derivative of general fo...  
JP5925381B2
The present invention relates to the compound [4-(2-amino-10-methyl-4-oxo-6,7,8,9-tetrahydro-4a,7-cycloimi no-pyrimido[4,5-b] [1,4] diazepine-5(4H)-yl)benzoyl]-glutamate (JK12A for short) with the structure of Formula I. The present inve...  
JP2016513116A
[Subject] New dihydro Pteridinone are provided. [Means for Solution] The present invention relates to a medicine constituent containing those use and the compound as a modulator of spiro heterocyclic * dihydro Pteridinone and gamma* secr...  
JP5916040B2
This invention is in the field of chemical restructuring of antimetabolite agents known to have poor oral bioavailability and to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concer...  
JP2016512814A
A synthesizing method and a useful constituent for a compound containing a linker molecule containing a Pteroyl ligand which is a compound useful as a near-infrared fluorescent probe, and it combines with i target receptor protein, ii dy...  
JP2016512813A
This indication is related with a compound useful as a near-infrared fluorescent probe containing a linker molecule containing a Pteroyl ligand combined with i target receptor protein, ii dye molecule and iii amino acid, or its derivativ...  
JP5876527B2
The present invention is directed towards novel folate-conjugates of formula I wherein F is a folate or derivative thereof, Z1, Z2, Z3 are independently of each other C or N, S1 to S4 are independently of each other a single bond or a sp...  
JP2015523383A5  
JP2016006111A
To provide a compound that is useful for the treatment of cancer and inflammatory disorder, and a pharmaceutical composition that contains the compound.Provided is: a compound comprising a substantially pure diastereomer of 10-propargyl-...  
JP5841548B2
The present invention relates to new dihydropteridinones of general formula (12) wherein the groups R1 to R5 and L, n, and m have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihy...  
JPWO2013168693A
Offer of a manufacturing process of sepia pterin, Lactoyl pterin, and tetrahydro Lactoyl pterin. Sepia pterin, Lactoyl pterin, and tetrahydro Lactoyl pterin are obtained with sufficient yield by the following equations.  
JP2016500065A
The present invention is formula (I) (inside of a formula, R).1R2W, X1X2X3X4And n provides the use for the medical treatment of superfluous proliferative diseases, such as a new imidazole * piperidinyl derivative which has the meaning sh...  
JPWO2013168693A1
Offer of the manufacturing process of sepia pterin, Lactoyl pterin, and tetrahydro Lactoyl pterin. Sepia pterin, Lactoyl pterin, and tetrahydro Lactoyl pterin are obtained with sufficient yield by the following equations.  
JPWO2013161913A1
It has a PDE2A selective inhibition operation, and provides a compound useful as prevention and curative medicines, such as schizophrenia and Alzheimer's disease. Formula (1): Each sign in [type is as given in a specification. The compou...  
JPWO2013161913A
It has a PDE2A selective inhibition operation, and provides a compound useful as prevention and curative medicines, such as schizophrenia and Alzheimer's disease. Formula (1) :Each sign in [type is as given in a specification. A compound...  
JP5802670B2
The present disclosure relates to 1- or 2-(4-(aryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and 1- or 2-(4-(heteroaryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and their use as agrochemicals and animal health products.  
JP5785622B2
A method for producing antifolate agents having glutamic acid part in their structure is developed by protecting carboxyl groups of glutamic acid or its N-substituted derivatives as cyanomethyl ester to give compounds of formula (II) whi...  
JP5781026B2
The invention provides a conjugate comprising ethylenedicysteine (EC) conjugated to neomycin.  
JP5767642B2
Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defi...  
JP2015523383A
The constituent for checking the activity of the method of using FGFR inhibitor, the medicine constituent containing this compound, and this compound for this specification and tyrosine kinase is indicated. In one mode, the present inven...  
JP2015518463A
The present invention is a carrier system for using it for target inclination type delivery and/or an antigen display system, and conjugate of it is carried out to one or more bioactive ligands, and it is aimed at the carrier system cont...  
JP2015110567A
To provide a stable complex of an alkaline earth metal salt of (6RS)- or (6S)-N-methyl-(5,6,7,8)-tetrahydrofolic acid and a polyol, and a method for producing the same.There is provided a complex of an alkaline earth metal salt of N meth...  
JP2015516445A
The present invention relates to a プテリジノン derivative as inhibitor of EGFR, BLK, and FLT3, and its application. Concretely, the present invention relates to use of the above-mentioned compound in manufacture of a medicine for ...  
JP2015516405A
The phenyl group within folic acid structure the present invention,18it was replaced with F* hetero ring -- new18When diagnosing the cell or cell mass who makes the radiopharmaceutical of F* folic acid / folic acid metabolic antagonist f...  
JPWO2013122112A
A prodrug of 2* nitroglycerine *1* imidazole propionic acid and a therapeutic active organic compound which has an amino group, an annular amino group, or a hydroxyl machine in a molecule, and a prodrug as which a therapeutic organic com...  
JPWO2013122112A1
The prodrug of 2* nitroglycerine *1* imidazole propionic acid and the therapeutic active organic compound which has an amino group, an annular amino group, or a hydroxyl machine in a molecule, and the prodrug as which a therapeutic organ...  
JP5710246B2
The present invention is directed towards novel folate-conjugates of formula I wherein F is a folate or derivative thereof, Z1, Z2, Z3 are independently of each other C or N, S1 to S4 are independently of each other a single bond or a sp...  
JP2015078229A
To provide lipids-therapeutic nucleic acid compositions useful for general therapeutic use.The present invention provides novel cationic lipids and lipid particles comprising the same. The lipid particles can further comprise active phar...  

Matches 651 - 700 out of 1,641